Breaking: Biolinerx (NASDAQ:BLRX) Buy Rating Maintained at Oppenheimer Today; The Price Objective is Set to $3.0

September 17, 2017 - By Marguerite Chambers

 Breaking: Biolinerx (NASDAQ:BLRX) Buy Rating Maintained at Oppenheimer Today; The Price Objective is Set to $3.0

Biolinerx (NASDAQ:BLRX) Rating Reaffirmed

Recently, In an analyst report shared with investors and clients on Tuesday morning, Biolinerx (NASDAQ:BLRX) shares have had their Buy Rating reiterated by expert analysts at Oppenheimer, who currently has a $3.0 target on company. This target by Oppenheimer indicates the possibile upside of 185.71 % from the current price.

Bioline RX Ltd (NASDAQ:BLRX) Ratings Coverage

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx has $7 highest and $3.0 lowest target. $3.83’s average target is 264.76% above currents $1.05 stock price. BioLineRx had 14 analyst reports since July 27, 2015 according to SRatingsIntel. Oppenheimer maintained the stock with “Buy” rating in Tuesday, August 8 report. The stock of Bioline RX Ltd (NASDAQ:BLRX) earned “Buy” rating by TH Capital on Monday, July 27. The company was maintained on Friday, May 26 by H.C. Wainwright. Maxim Group maintained Bioline RX Ltd (NASDAQ:BLRX) rating on Thursday, June 1. Maxim Group has “Buy” rating and $300 target. The rating was maintained by Maxim Group on Monday, July 10 with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 9. H.C. Wainwright maintained Bioline RX Ltd (NASDAQ:BLRX) on Friday, June 2 with “Buy” rating. The stock of Bioline RX Ltd (NASDAQ:BLRX) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. On Tuesday, August 8 the stock rating was maintained by Maxim Group with “Buy”. The stock of Bioline RX Ltd (NASDAQ:BLRX) has “Hold” rating given on Friday, August 12 by Maxim Group.

The stock increased 0.96% or $0.01 on September 15, reaching $1.05. About 125,334 shares traded. Bioline RX Ltd (NASDAQ:BLRX) has declined 6.10% since September 17, 2016 and is downtrending. It has underperformed by 22.80% the S&P500.

Wall Street await Bioline RX Ltd (NASDAQ:BLRX) to release earnings on November, 28. Analysts forecast earnings per share of $-0.05, up exactly $0.03 or 37.50 % from 2014’s $-0.08 EPS. After posting $-0.05 EPS for the previous quarter, Bioline RX Ltd’s analysts now forecast 0.00 % EPS growth.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. The company has market cap of $109.32 million. The Company’s clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. It currently has negative earnings.

More notable recent Bioline RX Ltd (NASDAQ:BLRX) news were published by: Seekingalpha.com which released: “BioLineRx: Expands Cancer Pipeline Significantly By Acquiring Novel Drug …” on March 27, 2017, also Prnewswire.com with their article: “BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of …” published on March 23, 2017, Seekingalpha.com published: “BioLineRx: At Around $1, This Sleeper Biotech Stock Is A Strong Buy” on July 13, 2017. More interesting news about Bioline RX Ltd (NASDAQ:BLRX) were released by: Seekingalpha.com and their article: “BioLineRx: Why I See Significant Upside Potential In This $1 Biotech Stock” published on September 01, 2017 as well as Seekingalpha.com‘s news article titled: “BioLineRx – Undervalued With Significant Pipeline, Large Pharma Collaborations …” with publication date: February 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.